Literature DB >> 15320816

Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis.

Ioanna Gouni-Berthold1, Agapios Sachinidis.   

Abstract

Elevated low density lipoprotein (LDL) cholesterol (LDL-C) levels represent one of the most important risk factors for atherosclerosis and therefore cardiovascular morbidity and mortality. LDL-C operates at different levels and through various classic and non-classic mechanisms. For example, it has been recently shown that both native and oxidized LDL are potent growth factors for several cell types such as vascular smooth muscle cells (VSMC) participating in the development and progression of atherosclerosis. Moreover, LDL-C modulates the expression of various growth factors and growth factor receptors that are involved in the process of atherosclerosis. More specifically, LDL-C can phosphorylate and therefore activate the epidermal growth factor (EGF) receptor and enhance the production of platelet derived growth factor (PDGF)-AA and of the PDGF receptors. LDL as well as oxidized LDL (oxLDL) signal transduction pathways involve trimeric G-proteins and cAMP, protein kinase C and ceramide, diacylglycerol and inositol-1,4,5-triphosphate, Ca(+2), Na(+)/H(+) exchange, c-fos and egr-1, phospholipases C, A2 and D, Raf-1, MEK1/2, the ERK1/2 (p42/44), SAP/JNK and p38 isoforms of the mitogen activated protein kinases (MAPK) as well as the signal transuding element gp 130. Furthermore, the mitogenic effects of oxLDL may be mediated by its oxidation products such as lysophosphatidylcholine (LPC), and lysophosphatidic acid (LPA), through LDL-induced lactosylceramide (LacCer) synthesis, and, as our group has recently shown, through LDL-adherent factors such as sphingosine-1-phosphate (S1P) and sphingosylphosphorylcholine (SPC). We review the various LDL-mediated signal transduction pathways implicated with the development and progression of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15320816     DOI: 10.2174/1570161043385466

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  5 in total

1.  Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits.

Authors:  Li-ming Ruan; Wei Cai; Jun-zhu Chen; Jin-feng Duan
Journal:  Int J Med Sci       Date:  2010-05-08       Impact factor: 3.738

Review 2.  Roles of lysophosphatidic acid in cardiovascular physiology and disease.

Authors:  Susan S Smyth; Hsin-Yuan Cheng; Sumitra Miriyala; Manikandan Panchatcharam; Andrew J Morris
Journal:  Biochim Biophys Acta       Date:  2008-06-10

Review 3.  The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile.

Authors:  Daria Brambilla; Cesare Mancuso; Mariagrazia Rita Scuderi; Paolo Bosco; Giuseppina Cantarella; Laurence Lempereur; Giulia Di Benedetto; Salvatore Pezzino; Renato Bernardini
Journal:  Nutr J       Date:  2008-09-30       Impact factor: 3.271

4.  Lysophosphatidylcholine up-regulates human endothelial nitric oxide synthase gene transactivity by c-Jun N-terminal kinase signalling pathway.

Authors:  Feiyue Xing; Jing Liu; Yongyan Mo; Zhifeng Liu; Qinghe Qin; Jingzhen Wang; Zhenhua Fan; Yutian Long; Na Liu; Kesen Zhao; Yong Jiang
Journal:  J Cell Mol Med       Date:  2008-06-20       Impact factor: 5.310

Review 5.  Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis.

Authors:  Xin Xu; Linlin Lu; Quanyong Dong; Xiaolin Li; Nannan Zhang; Yongning Xin; Shiying Xuan
Journal:  Lipids Health Dis       Date:  2015-12-03       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.